Physician profile
Brian E Davis
NPI 1932198124
$5,741.24
in general payments reported to CMS, 2019-2025
25 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,112 · 2022: $1,080 · 2023: $1,392 · 2024: $1,052 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,549.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,612.97 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,194.66 | 2021-2025 | Lifevest |
| Pfizer INC. | $871.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $399.96 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.02 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $205.49 | 2021-2024 | Xarelto |
| Abbott Laboratories | $188.15 | 2021-2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $128.55 | 2021-2025 | Eliquis, Camzyos |
| Abiomed | $124.90 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $119.11 | 2021-2024 | Brilinta, Andexxa |
| Boston Scientific Corporation | $98.93 | 2022-2024 | Watchman Access System |
| Amgen INC. | $98.00 | 2022-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $96.34 | 2025 | |
| Esperion Therapeutics, INC. | $82.90 | 2021 | |
| Cvrx, INC. | $51.46 | 2023-2024 | Barostim Neo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $50.15 | 2025 | Inspire |
| Atricure, INC. | $24.57 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.92 | 2023 | Arcalyst |
| Novo Nordisk INC | $17.85 | 2025 | Wegovy |
| United Therapeutics Corporation | $16.35 | 2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $15.55 | 2023 | Evkeeza |
| Medtronic, INC. | $15.28 | 2023 | Linq II |
| Heartflow, INC. | $14.52 | 2024 | |
| Kestra Medical Technology Services, INC. | $13.37 | 2023 | Assure Wcd |
| Cardiovascular Systems INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.